Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL614194 Target Snapshot

Panel NCI-60 (60 carcinoma cell lines) · CELL-LINE · Homo sapiens

Back to Search Search this target Browse approvals Evidence Card
881Compounds
159Assays
1Approved Drugs
31.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Research home Demo workspace
Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-14

Confirm a stable target identifier before relying on this context across project surfaces.

Review focus
Open DB context pending

Confirm a stable target identifier before relying on this context across project surfaces.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-14
Open source guide
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Panel NCI-60 (60 carcinoma cell lines) as ChEMBL target CHEMBL614194. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Panel NCI-60 (60 carcinoma cell lines)
CELL-LINE · Homo sapiens
As of 2026-09-14
ChEMBL target ID
CHEMBL614194
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-14
www.ebi.ac.uk
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-14
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether Panel NCI-60 (60 carcinoma cell lines) still has a stable protein naming contract across sources.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need the strongest disease program and evidence level in one place.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

Preferred NamePanel NCI-60 (60 carcinoma cell lines)
Target TypeCELL-LINE
OrganismHomo sapiens
ChEMBL ↗

Next Actions

SearchRun a focused querySearch the database using this target name as the starting context. ApprovalsCheck approved moleculesSee which approved drugs connect back to this target and its surrounding signal space. FeedScan papers & updatesStay in the project thread while checking recent papers and platform updates.
UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelPanel NCI-60 (60 carcinoma cell lines)
UniProt AccessionN/A

Panel NCI-60 (60 carcinoma cell lines)

Source · UniProt accession via ChEMBL component mapping
UniProt Context ↗
Review Cue

How to read this target

Review this target as Panel NCI-60 (60 carcinoma cell lines).

Review namePanel NCI-60 (60 carcinoma cell lines)
OrganismHomo sapiens
Clinical Profile

Clinical Phase Distribution

1
Approved
1
Phase II
Assay Mix

Activity Type Distribution

IC5031.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL5571407 7.75 IC50 17.98 Preclinical
CHEMBL487253 7.11 IC50 77.0 Approved
CHEMBL5184029 6.98 IC50 105.0 Preclinical
CHEMBL5277669 6.7 IC50 200.0 Preclinical
CHEMBL5171611 6.52 IC50 300.0 Preclinical
CHEMBL5172596 6.52 IC50 300.0 Preclinical
CHEMBL5194853 6.52 IC50 300.0 Preclinical
CHEMBL5204029 6.52 IC50 300.0 Preclinical
CHEMBL3404035 6.44 IC50 360.0 Preclinical
CHEMBL5188458 6.44 IC50 360.0 Preclinical
Distribution

pChEMBL Value Distribution

4
5.0
7
5.5
3
6.0
6
6.5
1
7.0
1
7.5
0
8.0
0
8.5
0
9.0
0
9.5
pChEMBL
Approved Drugs

Approved Drugs

BENDAMUSTINE
CHEMBL487253
Approved 2008
Properties Compare Identifier
Assay Landscape

Assay Landscape

159
Total Assays
25
Tested Compounds
3
Assay Types
Functional — 153 assays, 25 compounds
BAO Format Assays Compounds Avg pChEMBL
cell-based format 153 25 5.8
ADME — 4 assays, 0 compounds
BAO Format Assays Compounds Avg pChEMBL
cell-based format 4 0 —
Toxicity — 2 assays, 0 compounds
BAO Format Assays Compounds Avg pChEMBL
cell-based format 2 0 —

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine